Small Molecules in Oncology: Recent Results in Cancer Research, cartea 184
Editat de Uwe M. Martensen Limba Engleză Paperback – 4 mai 2012
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (3) | 824.34 lei 6-8 săpt. | |
Springer International Publishing – 5 ian 2019 | 824.34 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 23 aug 2016 | 888.08 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 4 mai 2012 | 1620.96 lei 6-8 săpt. | |
Hardback (2) | 715.79 lei 6-8 săpt. | |
Springer Berlin, Heidelberg – 12 mai 2014 | 715.79 lei 6-8 săpt. | |
Springer International Publishing – 13 aug 2018 | 831.14 lei 6-8 săpt. |
Din seria Recent Results in Cancer Research
- 5% Preț: 301.77 lei
- 14% Preț: 749.65 lei
- 5% Preț: 191.69 lei
- 5% Preț: 766.63 lei
- 5% Preț: 895.26 lei
- 5% Preț: 900.64 lei
- 5% Preț: 392.23 lei
- 15% Preț: 480.52 lei
- 5% Preț: 689.60 lei
- 5% Preț: 706.45 lei
- 5% Preț: 695.00 lei
- 5% Preț: 696.79 lei
- 5% Preț: 696.23 lei
- 5% Preț: 698.91 lei
- 5% Preț: 354.53 lei
- 5% Preț: 698.20 lei
- 5% Preț: 363.65 lei
- 5% Preț: 707.35 lei
- 5% Preț: 702.35 lei
- 5% Preț: 349.16 lei
- 5% Preț: 705.19 lei
- 5% Preț: 352.40 lei
- 5% Preț: 692.13 lei
- 5% Preț: 703.22 lei
- 5% Preț: 704.63 lei
- 5% Preț: 691.07 lei
- 5% Preț: 703.77 lei
- 5% Preț: 702.71 lei
- 5% Preț: 696.79 lei
- 5% Preț: 697.85 lei
- 5% Preț: 696.58 lei
- 5% Preț: 371.34 lei
- 5% Preț: 1067.62 lei
- 5% Preț: 353.82 lei
- 5% Preț: 697.85 lei
- 5% Preț: 701.10 lei
- 5% Preț: 702.35 lei
- 5% Preț: 706.10 lei
- 5% Preț: 693.56 lei
- 5% Preț: 717.19 lei
- 5% Preț: 701.44 lei
- 5% Preț: 708.44 lei
- 5% Preț: 361.68 lei
- 5% Preț: 695.00 lei
- 5% Preț: 698.20 lei
- 5% Preț: 697.15 lei
- 5% Preț: 704.83 lei
- 5% Preț: 694.81 lei
- 5% Preț: 695.72 lei
- 5% Preț: 710.06 lei
Preț: 1620.96 lei
Preț vechi: 1706.27 lei
-5% Nou
Puncte Express: 2431
Preț estimativ în valută:
310.27€ • 325.71$ • 256.30£
310.27€ • 325.71$ • 256.30£
Carte tipărită la comandă
Livrare economică 30 ianuarie-13 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783642261459
ISBN-10: 3642261450
Pagini: 256
Ilustrații: XVI, 238 p.
Dimensiuni: 155 x 235 x 13 mm
Greutate: 0.39 kg
Ediția:2010
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3642261450
Pagini: 256
Ilustrații: XVI, 238 p.
Dimensiuni: 155 x 235 x 13 mm
Greutate: 0.39 kg
Ediția:2010
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Recent Results in Cancer Research
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
Professional/practitionerCuprins
Protein kinase inhibitors.- Imatinib Mesylate.- Erlotinib.- Axitinib (AG-013736).- Lapatinib.- Sorafenib.- Sunitinib.- Dasatinib.- Nilotinib.- Bosutinib.- Epigenetic modifiers.- Decitabine.- 5-Azacytidine/Azacitidine.- Cell cycle inhibitors.- Bortezomib.- Temsirolimus.- Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor.- BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1).- Other novel agents.- Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy.- GDC-0449 - Targeting the Hedgehog Signaling Pathway.
Textul de pe ultima copertă
Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
Caracteristici
Provides a broad overview of the small molecules currently used for the treatment of malignant diseases Discusses interesting novel compounds that are in the process of clinical development to combat cancer Written by acknowledged experts Includes supplementary material: sn.pub/extras
Notă biografică
Uwe Martens, Prof. Dr. med., is chair of the Cancer Center Heilbronn-Franken and head of the Department of Hematology and Oncology at the SLK Clinic Heilbronn, which is an academic teaching hospital of the University of Heidelberg. He graduated in Medicine from the University of Freiburg and continued his medical and scientific training at the Medical University Center in Freiburg and at the BC Cancer Research Center in Vancouver. His scientific focus is the development of personalized cancer therapy and immunotherapy. He is a co-founder of the MOLIT Institute for Personalized Medicine at the science and technology park in Heilbronn, which aims to rapidly translate precision medicine into standard care.
Recenzii
“The book is recommended for healthcare professionals, scientists, and students in medical and scientific fields. In 25 well-written chapters, experts in their fields of research describe in great detail 12 compounds currently in clinical use for the treatment of hematological malignancies, and 13 compounds applicable to specific mutation-containing malignancies or aimed at interfering with the microenvironment (such as angiogenesis). … This book provides important practical information on a wide variety of novel small molecule-based treatment approaches.” (George Somlo, Doody's Book Reviews, April, 2015)